2024
Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
Moledina D, Obeid W, Smith R, Rosales I, Sise M, Moeckel G, Kashgarian M, Kuperman M, Campbell K, Lefferts S, Meliambro K, Bitzer M, Perazella M, Luciano R, Pober J, Cantley L, Colvin R, Wilson F, Parikh C. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. Journal Of Clinical Investigation 2024, 134: e180583. PMID: 38488004, PMCID: PMC10940080, DOI: 10.1172/jci180583.Peer-Reviewed Original Research
2023
Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
Moledina D, Obeid W, Smith R, Rosales I, Sise M, Moeckel G, Kashgarian M, Kuperman M, Campbell K, Lefferts S, Meliambro K, Bitzer M, Perazella M, Luciano R, Pober J, Cantley L, Colvin R, Wilson F, Parikh C. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. Journal Of Clinical Investigation 2023, 133: e168950. PMID: 37395276, PMCID: PMC10313360, DOI: 10.1172/jci168950.Peer-Reviewed Original ResearchConceptsUrinary CXCL9External validation cohortValidation cohortControl groupAIN diagnosisDiscovery cohortKidney tissueDiagnostic biomarkersAcute interstitial nephritisCXCL9 mRNA expressionAcute kidney injuryBiopsy-confirmed diagnosisAvailable clinical testsNational InstituteKidney injuryTubulointerstitial nephritisInterstitial nephritisKidney biopsyHistological confirmationHistological diagnosisTreatment optionsLymphocyte chemotaxisCXCL9MRNA expression differencesPatients
2021
Development and external validation of a diagnostic model for biopsy-proven acute interstitial nephritis using electronic health record data
Moledina DG, Eadon MT, Calderon F, Yamamoto Y, Shaw M, Perazella MA, Simonov M, Luciano R, Schwantes-An TH, Moeckel G, Kashgarian M, Kuperman M, Obeid W, Cantley LG, Parikh CR, Wilson FP. Development and external validation of a diagnostic model for biopsy-proven acute interstitial nephritis using electronic health record data. Nephrology Dialysis Transplantation 2021, 37: 2214-2222. PMID: 34865148, PMCID: PMC9755995, DOI: 10.1093/ndt/gfab346.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisInterstitial nephritisUrine biomarkersBiopsy-proven acute interstitial nephritisElectronic health record dataExternal validation cohortTypical clinical featuresBlood urea nitrogenTumor necrosis factorCharacteristic curve analysisHealth record dataExternal validationElectronic health recordsAIN diagnosisModest AUCsSerum creatinineCreatinine ratioKidney biopsyClinical featuresValidation cohortNecrosis factorUnrecognized casesInterleukin-9PatientsUrea nitrogen
2020
Is urine microscopy a useful early biomarker for cardiac surgeryrelated AKI?
Perazella MA. Is urine microscopy a useful early biomarker for cardiac surgeryrelated AKI? Brazilian Journal Of Nephrology 2020, 42: 1-3. PMID: 32129787, PMCID: PMC7213936, DOI: 10.1590/2175-8239-jbn-2019-0208.Peer-Reviewed Original Research
2015
The Urine Sediment as a Biomarker of Kidney Disease
Perazella MA. The Urine Sediment as a Biomarker of Kidney Disease. American Journal Of Kidney Diseases 2015, 66: 748-755. PMID: 25943719, DOI: 10.1053/j.ajkd.2015.02.342.Peer-Reviewed Original ResearchConceptsUrine sediment examinationKidney diseaseSediment examinationKidney conditionsUrine sedimentNovel urine biomarkersNew candidate biomarkersCentralized laboratory testingKidney injuryUrine biomarkersNew diagnostic technologiesUrinary biomarkersClinical practiceCandidate biomarkersTime-honored testsMaintenance of competencyDiagnostic panelDiagnostic testsDiseaseBiomarkersCliniciansUseful batteryExaminationDiagnostic informationDiagnostic technologies
2010
Experience with outpatient computed tomographic-guided renal biopsy.
Margaryan A, Perazella MA, Mahnensmith RL, Abu-Alfa AK. Experience with outpatient computed tomographic-guided renal biopsy. Clinical Nephrology 2010, 74: 440-5. PMID: 21084047, DOI: 10.5414/cnp74440.Peer-Reviewed Original ResearchConceptsNative kidney biopsiesKidney biopsyRenal biopsyPost-biopsy observation periodInpatient observation periodObservation periodLow complication rateTime of admissionYale-New Haven Medical CenterDuration of procedureInstances of deathHemoglobin concentration changesDetectable bleedingSerum creatinineComplication rateMean ageRenal sizeAdequate tissueMedical CenterOutpatient unitDiagnostic tissueBiopsyLaboratory dataTransfusionPatients
2001
Indinavir nephropathy revisited: A pattern of insidious renal failure with identifiable risk factors
Reilly R, Tray K, Perazella M. Indinavir nephropathy revisited: A pattern of insidious renal failure with identifiable risk factors. American Journal Of Kidney Diseases 2001, 38: e23.1-e23.6. PMID: 11576910, DOI: 10.1053/ajkd.2001.27732.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusRenal failureSerum creatinineRisk factorsDiffuse interstitial infiltratesElevated serum creatinineAcute renal failureIdentifiable risk factorsProgressive tubulointerstitial injuryIndinavir therapyFlank painHepatitis CTubulointerstitial injuryTubulointerstitial lesionsPositive patientsRenal injuryRenal biopsyInterstitial infiltratesImmunodeficiency virusNumerous eosinophilsFocal necrosisRenal syndromeProgressive riseIndinavirPotential mechanisms